With the rapid rise in popularity of artificial intelligence (AI) across various sectors throughout the United States and the European Union (EU), particularly in drug development and health care services, law departments are initially tasked with structuring sourcing activities to establish appropriate purchasing or deployment terms and governance for these new AI models and systems.
Over the course of two webinars, Epstein Becker Green and Bird & Bird offer practical guidance and tips for how the health care and life sciences industry can better manage this enterprise risk.
To watch the webinars on-demand, the buttons below will direct you to a registration page.
Session One (June 17, 2024)
- Transaction support and best practices in contracting provisions for the acquisition or deployment of machine learning models
- Intellectual property (IP) support and training data support, as these licensing deals are rife with IP issues
- Privacy and security, finding a way to comply with wide-ranging requirements at the international, national, state, and local realms
Watch the Recording
Session Two (June 21, 2024)
Due diligence considerations:
- Positive performance of the machine learning model
- Negative performance in areas such as discrimination and bias
AI governance:
- Guardrails that should be implemented on the use of the acquired and deployed AI
- Corporate organizational issues and alignment with existing policies
Regulatory compliance issues in the health care sector:
- Domain-specific regulatory requirements such as those that apply to Food and Drug Administration and EU medical devices
- EU AI Act requirements applicable to general-purpose AI models, and high-risk uses of AI systems
Watch the Recording
Session One Speakers
Moderated by Marc Martens and Feyo Sickinghe
|
Toby Bond Partner, Intellectual Property Bird & Bird |
|
|
Brian G. Cesaratto Member of the Firm Epstein Becker Green Email Me
|
|
|
|
|
Dr. Nils Lölfing Counsel, Tech & Coms Bird & Bird |
|
|
Marc Martens Partner and Co-Head of the International Life Sciences & Healthcare Group Bird & Bird
|
|
|
|
|
Feyo Sickinghe Principal Regulatory Counsel Bird & Bird |
|
|
Alaap B. Shah Member of the Firm Epstein Becker Green Email Me
|
|
|
|
|
Adelee Traylor Member of the Firm Epstein Becker Green Email Me |
|
|
Ben Woodfield Senior Associate, Commercial Bird & Bird
|
|
|
|
Session Two Speakers
Moderated by James P. Flynn
|
James Baillieu Partner, Corporate Bird & Bird |
|
|
James P. Flynn Managing Director / Member of the Firm Epstein Becker Green Email Me
|
|
|
|
|
Ann Henry Partner, Dispute Resolution Bird & Bird |
|
|
Marc Martens Partner and Co-Head of the International Life Sciences & Healthcare Group Bird & Bird
|
|
|
|
|
Chris Provan Data Scientist Mosaic Data Science |
|
|
Lynn Shapiro Snyder Member of the Firm Epstein Becker Green Email Me
|
|
|
|
|
Bradley Merrill Thompson Member of the Firm Epstein Becker Green Email Me
|
|
|
|
Co-Presented By
Contacts
If you have any questions, please reach out to Cat Rosario.
Members of the media, please contact Lori Anger.